drugset / Trial / NCT03484520
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).
Timeline
- Start
- 2018-07-23
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dinaciclib | Small molecule | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |